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Abstract
Antiviral pre-exposure prophylaxis (PrEP) through daily drug administration can protect healthy individuals from HIV-1
infection. While PrEP was recently approved by the FDA, the potential long-term consequences of PrEP implementation
remain entirely unclear. The aim of this study is to predict the efficacy of different prophylactic strategies with the pro-drug
tenofovir-disoproxil-fumarate (TDF) and to assess the sensitivity towards timing- and mode of TDF administration (daily- vs.
single dose), adherence and the number of transmitted viruses. We developed a pharmacokinetic model for TDF and its
active anabolite tenofovir-diphosphate (TFV-DP) and validated it with data from 4 different trials, including 4 distinct dosing
regimes. Pharmacokinetics were coupled to an HIV model and viral decay following TDF mono-therapy was predicted,
consistent with available data. Subsequently, a stochastic approach was used to estimate the % infections prevented by (i)
daily TDF-based PrEP, (ii) one week TDF started either shortly before, or -after viral exposure and (iii) a single dose oral TDF
before viral challenge (sd-PrEP). Analytical solutions were derived to assess the relation between intracellular TFV-DP
concentrations and prophylactic efficacy. The predicted efficacy of TDF was limited by a slow accumulation of active
compound (TFV-DP) and variable TFV-DP half-life and decreased with increasing numbers of transmitted viruses. Once daily
TDF-based PrEP yielded ƒ80% protection, if at least 40% of pills were taken. Sd-PrEP with 300 mg or 600 mg TDF could
preventƒ50% infections, when given at least before virus exposure. The efficacy dropped toƒ10%, when given 1 h before
24 h exposure. Efficacy could not be increased with increasing dosage or prolonged administration. Post-exposure
prophylaxis poorly prevented infection. The use of drugs that accumulate more rapidly, or local application of tenofovir gel
may overcome the need for drug administration long before virus exposure.
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Introduction
Tenofovir disoproxil fumerate (TDF) is an antiviral pro-drug,
belonging to the class of nucleoside reverse transcriptase inhibitors
(NRTIs) used for the treatment of the human immunodeficiency
virus 1 (HIV-1) [1] and hepatitis B. For HIV-1 treatment, it is
currently recommended as a backbone component in first-line
highly active antiretroviral therapy (HAART) [2]. TDF is
administered orally. After first pass of TDF through the liver,
tenofovir (TFV), an analogue of the endogeneous deoxyadenosine
monophosphate (dAMP) [3], is formed. TFV is also the
predominant circulating form [4,5]. After uptake into HIV target
cells, TFV can become sequentially phosphorylated to form
tenofovir diphosphate (TFV-DP), the active form, which is an
analog of endogeneous deoxyadenosine triphosphate (dATP).
TFV-DP subsequently competes with dATP for incorporation
into nascent viral DNA during HIV-1 reverse transcription (RT),
where it prevents further DNA polymerization during RT, once it
becomes incorporated [6]. TFV-DP thus prevents the production
of pro-viral DNA, which is required for stable host cell infection
and viral replication.
While most studies characterize the pharmacokinetics of TFV in
the blood plasma e.g. [7–10] only a few studies [11,12] focus on
the intracellular pharmacokinetics of the active anabolite, TFV-
DP, or establish a link between the pharmacokinetics of TFV in
plasma and TFV-DP in the intracellular space [13,14], which is
particularly important, since the plasma pharmacokinetics of
NRTIs and the pharmacokinetics of their active intracellular
anabolites are often nonlinearly related and temporally asynchro-
nous e.g. [15,16]. Thus, for establishing the link between dose and
response, the link between plasma- and intracellular pharmaco-
kinetics is essential, and can subsequently be used to predict the
effect of drug administration on virus dynamics. This complete
PK-PD link for NRTIs has only rarely been achieved [17]. For
TDF, no in silico model exists to the authors’ knowledge, which
integrates dosing, pharmacokinetics and antiviral response.
While TDF is an important drug for HIV treatment, it is also
being evaluated as a core component of pre-exposure prophylaxis
regimens (PrEP) to prevent HIV infection [18]. Interim reports
indicate variable outcomes for PrEP strategies: Whereas some
trials report no benefit of PrEP regimens (FEM-PrEP) [19], others
report 44 % to 73 % reduced HIV acquisition [20–22]. While the
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efficacy of TDF-based PrEP may depend on the mode of
transmission (hetero- vs. homosexual, or by needle-stick infection),
it is often argued that prophylactic success could be affected by
how strictly patients adhere to their (TDF-based) regimen [23].
Based on the average half life of TFV-DP in peripheral blood
mononuclear cells (PBMCs) it has been previously stated that TDF
is pharmacologically ‘‘forgiving’’ in the context of poor adherence
[3]. However, TFV-DP pharmacokinetics indicate a large inter-
patient variability [11,14], potentially leading to heterogeneous
protection in patients that equally adhere to their TDF-based
regimen. Also, adherence in some patients in clinical trials may
have been even lower than the pharmacological ‘‘forgiveness’’ of
the drug [24].
The goal of the present study is to provide an in silico model that
consistently predicts intracellular TFV-DP pharmacokinetics
based on different TDF dosing schemes. Subsequently, we use
previously published direct pharmacodynamic models to ultimate-
ly link the pharmacokinetics of oral TDF to its clinical response.
Once this link is established, we use stochastic simulation to
predict the relative infection risk, when TDF-based PrEP or mixed
PrEP/PEP strategies are applied with different levels of adherence
and timing of TDF administration and we point out factors that
may impair TDF-based PrEP. In view of the recent approval of
truvada (300 mg TDF + 200 mg emitricitabine (FTC)) for PrEP
by the FDA, this may raise awareness, encourage experimental
assessment and help to avoid the misuse of TDF-based PrEP.
Materials and Methods
Pharmacokinetic & Pharmacodynamic Data
TFV concentrations in blood plasma following either doses of
75, 150, 300 or 600 mg oral TDF were taken from three
independent clinical trials [7,9,12] and used to verify pharmaco-
kinetic model selection and evaluation (see Table S1). Individual
intracellular elimination of TFV-DP was assessed using the data
from [11], which observe the decline of TFV-DP in PBMCs after
discontinuation of TDF treatment (see Table S2). After successful
development of the pharmacokinetic model, it was coupled to a
model of viral dynamics and used to predict antiviral efficacy of 28
days TDF monotherapy in asymptotically infected individuals
following 75, 150, 300 or 600 mg oral TDF dosing, simultaneously
estimating the PK-PD coupling parameter IC50 (fifty percent
inhibitory concentration) and testing different alternative models
for intracellular uptake and anabolism of TFV. Predicted viral
load kinetics were compared to viral load data from [12]
(pharmacodynamic endpoint) and used for model selection (see
Text S1). The final coupled pharmacokinetic-pharmacodynamic
model was used to predict the prophylactic efficacy of TDF for a
wide range of parameter sets using stochastic simulation
techniques.
Assessment of Alternative Pharmacokinetic Models
We assessed different pharmacokinetic models for TFV in
plasma after 75-, 150- 300- and 600 mg dosing in line with
available trial data [7,9,12] and followed a stepwise model-
building process, in which the following reasonable assumption
was made: We neglected the impact of intracellular TFV-DP
pharmacokinetics on the plasma pharmacokinetics of TFV, since it
can be assumed to marginally influence the overall pharmacoki-
netics of TFV (total mass of TFV-DP in PBMCs is extremely
small: Ccell:VPBMCƒ0:0008mg; total volume of PBMCs:
ƒ1:10{6L [25,26]; plasma volume &3.5L). This assumption
allowed us to independently develop the plasma pharmacokinetics
model and then subsequently model the influx and conversion of
TFV to intracellular TFV-DP, depending on the actual TFV
concentration in blood plasma.
The pharmacokinetic model building process was guided by
goodness-of-fit and comparative model assessment in terms of
Akaike information. Pharmacokinetic parameters were estimated
by minimizing the weighted residual sum of squared errors









were Pj is a vector of pharmacokinetic parameters for candidate
model j, ~Yj(ti,Pj) are model-predicted TFV or TFV-DP
concentrations for parameter set Pj at time ti and Y (ti) are the
corresponding observed concentrations. Candidate models j were
then comparatively assessed using Akaike’s information criteria
(AIC), where the AIC-value of the jth model has been computed
according to [27]:
AIC(j)~nt: log (WRSE(j))z2:nP(j) ð2Þ
where nt denotes the number of observations and nP(j) denotes the
number of parameters required for the jth model. Subsequently,
the model with the best (the lowest) AIC was selected and further
used.
Final Pharmacokinetic Model
Based on predictive performance and Akaike information (see
Table 3) we found that two compartments (plus a dosing
compartment) best described TFV plasma pharmacokinetics, in
line with previous studies [13,14,28]. A third compartment was
used to model the pharmacokinetics of intracellular TFV-DP
[13,14]. Intracellular pharmacokinetics of TFV-DP were linked to
the plasma concentration via saturable uptake and anabolism
(Vmax(i) and Km) with individual maximum velocity of uptake and
anabolism and individual first order elimination kinetics kout(i)
(see Table S2), which best described the available data (see Text
S1). The final model for the TFV plasma- and intracellular TFV-
DP pharmacokinetics is illustrated in Figure 1A. The TFV/TFV-
DP pharmacokinetic model constitutes four compartments: D(t)
represents the mass of tenofovir in the dosing reservoir. C1 is the
central compartment, which represents the plasma concentration
of TFV. The second compartment C2 represents the poorly
perfused (peripheral) tissues and the cellular compartment Ccell
resembles the concentrations of TFV-DP in peripheral blood
mononuclear cells (PBMCs). Parameters k12 and k21 are the rate
constants for influx and outflux to-/from the peripheral compart-
ment C2 and ka and ke are the rates of TFV uptake and
elimination into/out of C1 respectively. All final parameters are
represented in Table 1. The value for ka and the bioavailability
Fbio were fixed to 1 h
{1 [28] and 0.32 [12] respectively, while all
other parameters were estimated.
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where V1 represents the volume of the central compartment. The
parameters Vmax(i) and Km describe the (saturable) processes of
TFV-uptake and conversion to TFV-DP within PBMCs, while
kout(i) denotes the rate of elimination of TFV-DP from the
PBMCs, which was found to vary between distinct patients (see
Table S2 and model comparison in Text S1). The concentration




where D(ti{1) denotes the mass of TDF in the dosing
compartment at the last dosing event ti{1. The parameter d(t)
denotes a delta dirac function which takes the value 1 at the
discrete dosing events t~ti and is otherwise zero.
Viral Dynamics
In order to predict (i) viral load kinetics following TDF
treatment in HIV-infected patients and (ii) the infection probabil-
ity for uninfected individuals, we adopted the virus dynamics
model from [29,30], which is depicted in Figure 1B. For predicting
viral load kinetics in infected individuals, we used the deterministic
infected (drug-free) fix-point of the model as a starting condition
and then monitored viral dynamics following TDF monotherapy.
For assessing the infection probability, we used the uninfected fix-
point of the model as starting condition and inoculated the
respective number of infectious viruses to simulate viral challenges.
In brief, the virus dynamics model comprises T-cells, macro-
phages, free non-infectious virus (TU,MU,VNI, respectively), free
infectious virus VI, and four types of infected cells: infected T-cells
and macrophages prior to proviral genomic integration (T1 and
M1, respectively) and infected T-cells and macrophages after
proviral genomic integration (T2 and M2, respectively). The
average rates of change of the different species are given by the









Figure 1. Pharmacokinetic model of TFV and intracellular TFV-DP and model of viral kinetics. A: Pharmacokinetic model. Parameters ka
and ke are the absorption and elimination rate constants of the central compartment C1 (which resembles plasma pharmacokinetics of TFV)
respectively. The parameters k12 and k21 denote the influx and outflux rate constant to-/from the peripheral compartment C2 respectively. Both
compartments (central-/peripheral-) have the same volume of distribution V1 . The dotted line from the central compartment to the intracellular
compartment C3 represents subsumed processes, namely the cellular uptake of TFV and subsequent phosphorylation to TFV-DP, which were related
to the plasma concentration of TFV (C1) by Michaelis-Menten kinetics, with parameters Km and individual parameter Vmax(i). The parameter kout(i) is
the individual, cellular elimination rate constant of TFV-DP. B: Virus dynamics model. T-cell and macrophage target cells (TU , MU) can become
successfully infected by infective virus VI with lumped infection rate constants bT and bM, respectively, creating early infected cells T1 and M1.
Infection can also be unsuccessful after the irreversible step of fusion (rate constant CLT and CLM, dashed lines), eliminating the virus and rendering
the cell uninfected. Early infected cells T1 andM1 can destroy essential viral proteins or DNA prior to integration with rate constants dPIC,T and dPIC,M
(dashed lines) returning the cell to an uninfected stage. The genomic viral DNA can become integrated with rate constants kT and kM creating late
infected cells T2 and M2 , which can release new infectious- and non infectious virus VI and VNI with rate constants NT, cNT{NT  and
NM, dNM{NM , respectively. All cellular compartments x can get destroyed by the immune system with respective rate constants dx and the free
virus gets cleared with rate constant CL (thin dashed lines). The pharmacologically active form of tenofovir (tenofovir-diphosphate, TFV-DP, green
box) inhibits successful cell-infection (parameter bT=M) and increases the rate of unsuccessful infection (parameter CLT=M).
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where lT and lM are the birth rates of uninfected T-cells and
macrophages, and dT and dM denote their death rate constants. The
parametersdPIC,T anddPIC,M refer to the intracellular degradation of
essential components of thepre-integration complex, e.g., by thehost
cellproteasome,whichreturnearly infectedT-cellsandmacrophages
to an uninfected stage, respectively. Parameters bT(t) and bM(t)
denote the rate of successful virus infection of T-cells and
macrophages in the presence of TFV-DP, respectively, while the
parametersCLT(t)andCLM(t)denotetheclearanceofvirus through
unsuccessful infection of T-cells and macrophages [29] in the
presence of TFV-DP at the respective time t. Parameters kT and kM
are the rate constants of proviral integration into the host cell’s
genome and cNT and dNM denote the total number of released
infectious and non-infectious virus from late infected T-cells and
macrophages and NT and NM are the rates of release of infectious
virus. The parameters dT1 ,dT2 ,dM1 and dM2 are the death rate
constants of T1,T2,M1 and M2 cells, respectively. The free virus
(infectious and non-infectious) gets cleared by the immune system
with rate constantCL.
Pharmacokinetic-Pharmacodynamic Coupling
We have previously shown that the antiviral effect of NRTIs (like
TDF) can be regarded by an inhibition of the rate of successful cell
infection bT=M and a proportional increase in the number of









where (1{g(t)) denotes the residual infection, when TFV is applied
and rrev&0:5 [31] is the probability that infection is successful in the







where IC50 denotes the intracellular TFV-DP concentration
(compartmentCcell in Fig. 2A), which reduces cell infection by 50%.
Prediction of Relative Infection Risk in the Presence of
TDF
Although per-contact infection probabilities have previously
been estimated for different routes of HIV transmission [33,34]
(e.g. &0.5–4% for homosexual receptive contact), it is not known
how much infectious virus actually reaches a cellular environment
that facilitates its reproduction (further on referred to as ‘inoculum
size’). Moreover, several (unknown) co-factors may alter this
number. It could be possible that virus does not reach a cellular
environment that facilitates its reproduction during the majority of
sexual contacts, as indicated by low per-contact-transmission
probabilities [34]. During those sexual contacts where infection
occurs, the data from [35,36] indicate that a small number of
founder particles (estimated to be of the order 1–5 in the majority
of infections) establish the viral population within the newly
infected individual. However, due to the inherent uncertainties
about the co-factors that potentially alter the number of
transmitted viruses, we will not compute relative per-contact-
infection probabilities under TDF administration, but rather
compute the percentage of infections prevented for distinct
inoculum sizes, relative to the absence of drug. The relative
infection probability is typically assessed in clinical trials from a
cohort of patients, without detailed knowledge of the viral
inoculum sizes and the circumstances of transmission.
In the simulations, infection was irreversible by the time that the
predicted number of viruses exceeded 1 million particles (because
the system behaves deterministically and approaches its infection
fix-point). Therefore, we recorded an infection event during our
simulations, whenever the viral population crossed this threshold
in a previously uninfected ‘virtual patient’ at risk. The percentage
infections prevented, when TDF is taken prophylactically was then






where P(inf:DVt0 ,w) is the probability of infection in the absence of
drugs w, when Vt0[f1,5,20,100g infectious viruses come into
Table 1. Pharmacokinetic and pharmacodynamic
parameters.
param. value param. value
ke {10.12 h V1 244 L
k12 {10.2926 h gkout {10.006,# [0.002;0.026] h
k21 {10.1537 h ka
z1
IC50 {175.7 mg. L bioF {0.32
Km {129.3 mg. L gVmax {11.44} [0.5;24] mg. L{1 . h
median parameter and range. # see Table 4 for individual values. z value set
to 1 [28]. { parameter from [12]. } computed using eq. (S2), Text S1.
doi:10.1371/journal.pone.0040382.t001
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contact with a cellular environment that facilitates their repro-
duction within the susceptible individual. The predicted probabil-
ity of infection in the absence of drugs P(inf :DVt0 ,w) was 10+
1:3%, 40+2:1%, 87+1:5% and 100+0%, respectively, when
Vt0 =1, 5, 20 or 100 viruses were inoculated. P(inf :DVt0 ,S) is the
corresponding probability of infection when prophylactic strategy
S is used. We evaluated the following TDF-based prophylactic
strategies: a) 300 mg oral TDF taken once daily when 20, 40, 60,
80 or 100% of pills are ingested, b) TDF is taken around the time
of viral exposure (6, 1 h before exposure or 1, 6, or 48 h after
exposure) and continued for 7 days (1w-PrEP/PEP) or c/d) a
single oral dose of 300 or 600 mg TDF is taken at either 1, 6, 12,
24 or 48 hours before exposure to virus (sd-PrEP).
During strategy a) (once daily oral TDF) adherence was
implemented using a ‘‘roulette-wheel selection’’ technique: A
uniformly distributed random number r on the open interval (0,1)
is drawn at each potential dosing time (each 24 hours of simulated
time). If this random number r is less than or equal to the
adherence level (e.g. rƒ0:4 for adherence level 40%), then a dose
is given to the virtual patient; otherwise not.
Modeling the infection probability requires to regard the
intrinsic stochasticity and discreteness of the infection event:
Either the transmitted virus becomes entirely cleared by the
immune system before establishing stable infection, or the
infection expands and disseminates throughout the body [18].
Reverse transcriptase inhibitors like TDF decrease the probability
of cell infection and therefore increase the probability that HIV
Figure 2. Pharmacokinetics of TFV for different doses of oral TDF at plateau and intracellular TFV-DP concentrations after
treatment cessation. A: Predicted pharmacokinetics of TFV after once daily 75-, 150-, 300- and 600 mg oral TDF (lines) together with data from
[7,9,12] (markers). B: Goodness-of-fit plot for the plasma pharmacokinetics of TFV with data from 3 clinical studies and 4 different dosing schemes
[7,9,12]. The dashed red line indicates the line of unity, whereas the green squares, -diamonds, triangles and filled dots represent the observed TFV
concentrations in [12] following 75-, 150-, 300- or 600 mg once daily administration of TDF. The blue left-pointing triangles and the magenta right-
pointing triangles represent observed TFV concentrations after 300 mg once daily oral administration from [9] and [7] respectively. C: Predicted
pharmacokinetics of intracellular TFV-DP after stopping of 300 mg once daily oral TDF dosing (lines) together with data from [11] (markers). D:
Goodness-of-fit plot for intracellular TFV-DP. The up- and downward pointing filled and open triangles, open- and filled circles, filled squares and
filled diamonds indicate intracellular TFV-DP pharmacokinetics after stopping 300 mg once daily oral TDF dosing in 8 different individuals from [11].
doi:10.1371/journal.pone.0040382.g002
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can become entirely cleared before establishing stable infection
[37]. In order to fully regard the intrinsic stochasticity of rare
events in the utilized model and to predict the impact of PrEP on
HIV transmission, we use the stochastic-deterministic simulation
algorithm presented in [30]. Unless otherwise stated, we ran 2000
stochastic-deterministic simulations for each parameter set to
estimate the infection probabilities with sufficient statistical
confidence.
Results
Plasma & Intracellular Pharmacokinetics
Predicted concentration-time profiles of TFV after 75-, 150-,
300- and 600 mg once daily dosing of TDF using the final
pharmacokinetic model (eqs. (3)-(6)) are shown in Fig. 2A (lines)
together with available data from 3 clinical trials [7,9,12]
(markers). It can be seen that TFV rapidly appears in the plasma
(tmax&2 h) and decays in a bi-phasic manner for all analyzed
dosing schemes. The estimated terminal half life of plasma TFV
was &19 hours, in line with previous estimates [3]. TFV
concentrations increase proportionally with increasing dose,
indicating dose-linear pharmacokinetics. A goodness-of-fit plot
with regard to plasma concentrations is shown in Fig. 2B. The plot
indicates an overall spread around the line of unity, supporting the
predictive power of the model. The predicted decay behavior of
TFV-DP in PBMCs after stopping TDF dosing is shown in Fig. 2C
together with available data [11]. The grey area therein indicates
the predicted range of kinetic behavior, whereas the solid red line
indicates the estimated median TFV-DP decay. Note that the
variation (grey range) is quite large, which is however in line with
other studies [14]. A goodness-of-fit plot with regard to individual
predicted vs. observed intracellular TFV-DP concentrations is
shown in Fig. 2D for the data coming from the distinct patients
(markers). The predicted average half life of TFV-DP was very
large (125h&gt1=2~ ln (2)=gkout). Overall, the plot indicates a
spread around the line of unity (dashed red line in Fig. 2D),
supporting the approach chosen for estimating individual decay
kinetics of TFV-DP in peripheral blood mononuclear cells
(PMBCs) rather than using an average value for all patients (see
also model comparison in Text S1).
The predicted concentration time profile of TFV-DP after a
single dose of 300 mg oral TDF is shown in Fig. 3A. It can be seen
that TFV-DP reaches its maximal concentrations after a median
time of 85 h (range: 49–113 h) following a single dose of TDF.
The maximally achievable concentrations vary between individ-
uals and are within the range of 7.6 to 163 fmol/106 cells (median
value: 16 fmol/106 cells) in case of a single dosing event.
The accumulation of intracellular TFV-DP in the case of daily
300 mg oral TDF is shown in Fig. 3B. TFV-DP trough
concentrations (concentrations immediately before the next dose)
reach their plateau levels after a median of 21 once daily dosing
events (range 10–36). On the contrary, plateau levels of the parent
compound TFV are reached within 7 dosing events in blood
plasma already (data not shown).
Antiviral Efficacy During Mono-therapy in HIV-infected
Individuals
For further model evaluation and estimation of the remaining
parameters IC50 and Km, we coupled the pharmacokinetics of
intracellular TFV-DP to an established model of the HIV-life cycle
[28,30] (see Methods section) and subsequently predicted the 56
days viral dynamics in asymptomatically HIV infected individuals
following a 28 days mono-therapy (day 0–28) with either 75-, 150-,
300- and 600 mg TDF. Our predictions are shown in Fig. 4A, B,
C, D together with data from the corresponding dose escalation
study [12]. The dashed lines and open circles in Fig. 4A, B, C, D
indicate clinically observed median log10 viral load decay from
[12], whereas the solid lines and filled circles indicate the predicted
median log10 viral decay using our model. The respective weighted
residual sum of squared errors WRSE (see eq. (1)), denoting the
Figure 3. Predicted TFV-DP intracellular pharmacokinetics following a single dose oral 300 mg TDF and accumulation of TFV-DP
after daily 300 mg oral TDF. A: Predicted intracellular pharmacokinetics of TFV-DP in PBMCs after a single 300 mg oral TDF dose. Solid black circle
and horizontal error bar indicate the tmax value and its range. B: Trough levels of TFV-DP in PBMCs following 300 mg oral TDF every 24hours,
indicating the accumulation of active compound. The solid black circle and the horizontal error bar indicate the time until plateau concentrations are
reached and the range for this parameter. Blue cirles, black squares, green diamonds, red downward pointing triangles, magenta upward-pointing
triangles, cyan right-ward pointing triangles, black left-pointing triangles and blue asterisks indicate individual predictions for 8 patients.
doi:10.1371/journal.pone.0040382.g003
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absolute deviation between experimental and predicted viral load
decay is shown in Text S1 (the Table therein) and indicates an
overall good predictive power of the coupled PK-PD model.
Notably, the experimental median viral decay profile for the
300 mg dose group indicated maximally achievable viral decay, as
the 600 mg dosing could not produce steeper viral decay than the
300 mg scheme.
Efficacy of Daily TDF for the Prevention of HIV-1 Infection
The predicted percent infections prevented by continuous once
daily 300 mg TDF PrEP are shown in Fig. 5A. It can be seen that
continuous PrEP can avert &80% infections, under 100%
adherence and with small inoculum sizes (1 infectious virus).
Under a fivefold increase in inoculum size, TDF is still efficacious,
preventing &75% of infections. However, if the inoculum size is
further increased (100 infectious viruses come into contact with
target cells), the efficacy drastically drops to levels of &20%
protection. On the other hand, imperfect adherence above the
level of 40% has only a small impact on the predicted
efficaciousness of TDF, confirming previous pharmacologic
considerations about the pharmacokinetic forgiveness of the drug
[3]. We statistically tested whether adherence and inoculum size
impact on the efficacy of TDF-based PrEP, based on our
simulation results. We found that decreasing adherence has a
small impact of the efficacy of TDF-based PrEP (infection
probabilities are not significantly altered if adherence is as low
as 60%). However, if adherence is below 40%, TDF-based
protection is significantly altered (p v 0.05). Furthermore, when
large numbers of viruses become transmitted, we observe a
stronger impact of adherence (see Fig. 5A). The inoculum size
determined the efficacy of TDF-based PrEP for all conditions
tested (p v 0.01, see Table S3).
In summary, the protective effect of TDF appears to be much
less sensitive to poor adherence (as long as adherence is above
40%), but is dependent on the actual mode of transmission, i.e.
how many viruses become transmitted. Notably, in a substudy of
Partners PrEP (serodiscordant couples in Kenya/Uganda) using
TDF only, an overall efficacy of 62% (confidence interval:
34%;78%) was reported, which corresponds to our predictions
for the case when small numbers of viruses become transmitted
(inoculum size 1–20 in Fig. 5A). The number of distinct founder
viruses was estimated to be rather low (of the order 1–5 for
heterosexual- and homosexual transmission) [35,36], which
stresses the importance of PrEP efficacy at low inoculum sizes
for the prevention of HIV-1 transmission and supports the
predictive power of our model.
Efficacy of One Week extended TDF prophylaxis during
Viral Exposure
We predicted the efficiency of TDF when started either 6 or 1 h
before exposure or 1, 6, or 48 h after exposure and continued for
7 days (1w-PrEdP/PEP). The results (see Fig. 5B) indicate a
maximally achievable efficacy of 1w-PrEP/PEP of &30% when
started 6h before viral challenge for small inoculum sizes. The
maximum achievable efficacy was similar to the sd-PrEP regimen.
The efficacy of 1w-PrEP/PEP was influenced by inoculum size (p
v 0.01, for all tested conditions, see Table 6) and dropped
drastically as the inoculum size increased. 1w-PrEP/PEP efficacy
was also affected by the timing of TDF initiation, particularly for
large inoculum sizes (p v 0.05, see Fig. 5B), with earlier times of
regimen initiation resulting in higher efficacy. Overall, our
predictions indicate that extended (one week) prophylaxis with
TDF initiated shortly before viral exposure offers little benefit
compared to sd-PrEP (Figure 5C, D). If TDF is initiated after viral
exposure, its efficacy is rather limited.
A recent investigation showed that 28 days of a post-exposure
prophylactic triple drug regimen containing TDF [38–40] is safe,
but data indicating the efficiency is missing for TDF alone or TDF
containing regimen in humans. Efficacy of PEP using tenofovir has
to date only been demonstrated in non-human studies, e.g.
[41,42]. The conducted experiments, however, indicate that the
prophylactic efficacy of post-exposure TDF may depend on the
type of virus used [43] and on particular pharmacokinetics,
possibly limiting the translation of these results to TDF-based PEP
in human.
Efficacy of Single Dose TDF Prophylaxis Shortly before
Exposure (sd-PrEP)
We tested the efficacy of single dose 300- and 600 mg oral TDF
given either 1, 6, 12, 24 or 48 h before viral exposure in Fig. 5C, D
respectively. Notably, sd-PrEP could reach a maximum efficacy of
&50% with small inoculum sizes, when given 24 hours prior to
exposure. The efficacy dropped gradually when the inoculum size
increased. In particular, sd-PrEP was completely inefficient when
large inoculum sizes were encountered (if§ 100 infectious viruses
come into contact with target cells). The dependency of sd-PrEP
efficacy on inoculum size was significant for all tested conditions at
the p v 0.01 level (Table S5, S6). Despite a dependency on the
inoculum size, sd-PrEP efficacy was also significantly altered by
the timing of drug administration, see Figure 5C, D. Generally
speaking, sd-PrEP efficacy was highest if TDF was taken 12–48 h
before viral exposure and almost completely inefficient when taken
only 1 h before exposure, which limits it’s practical use as a single-
dose prevention drug. The poor efficacy of sd-PrEP, as well as the
dependency on the timing of TDF administration is based on its
pharmacokinetics: TFV-DP, the active moiety, requires approx-
imately 21 (range: 10–36, see Fig. 3B) dosing events to reach
plateau levels and to exert its maximum effect. During single dose
administration, TFV-DP still requires about 85 h hours (range:
49–113, see Fig. 3A) to reach maximum concentrations Cmax.
Therefore, TDF needs to be taken early enough (§ 48 hours) to
allow for intracellular TFV-DP levels to build up. Once TFV-DP
levels have been achieved, they persist in most patients, owing to
the long half life of intracellular TFV-DP.
We also tested whether the effect of single dose TDF PrEP could
be potentiated, if the standard dose was doubled (see Figure 5D).
The prophylactic efficacy was, however, not markedly different for
most conditions tested, see Fig. 5C&D and Table S7 for a
statistical evaluation.
Relation between Intracellular TFV-DP Concentrations
and Prevention of HIV-1 Infection
We have derived an analytical formula in Text S2 to assess the
relation between intracellular TFV-DP concentrations and the %
HIV-1 infections prevented. The percent infections prevented by
distinct intracellular TFV-DP concentrations is shown in Fig. 6
(based on the analytic solution). It can be seen that the EC50 value
(concentrations of intracellular TFV-DP necessary to prevent 50%
of HIV-1 infections) is increasing for larger virus inoculum sizes.
The computed EC50 values were 29, 40, 77 fmol/10
6 cells for
inoculum size 1, 5 and 20 respectively, which is below the
concentration range achieved when 300 mg TDF is given once
daily in an adherent patient (dark grey area in Fig. 6). On the
contrary, the EC50 for a viral inoculum size of 100 is above the
concentration range typically achieved during once daily PrEP
with 300 mg TDF (EC50~411 fmol/10
6 cells). TFV-DP concen-
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trations to prevent 90% infections EC90 were 267, 348, 640 and
2866 fmol/106 cells for virus inoculum size 1, 5, 20 and 100
respectively (see Fig. 6).
Discussion
The plasma pharmacokinetics of TFV were best described by a
two compartment model (compartments C1 and C2) with first
order absorption and elimination, based on statistical model
comparison. Similar models were also used by most other groups
to describe the pharmacokinetics of TFV in blood plasma
[14,28,44,45]. Pharmacokinetic parameter estimates (Table 1)
agree well with previous studies [14], indicating a large volume of
distribution, bi-phasic decay with a particularly slow terminal half
life of &19 h, in line with previous estimates [3]. Inter-individual
variations in parameter values characterizing plasma pharmaco-
kinetics were estimated to be small in related studies [14,28,44]
(coefficient of variation less than 50%). We therefore decided to
ignore inter-individual variations in parameters describing the
plasma pharmacokinetics of TFV. To the contrary, parameters
describing the intracellular pharmacokinetics of TFV-DP display a
large inter-individual variability (in our model this affects
parameters kout and Vmax).
NRTIs like tenofovir exert their effects through their intracel-
lular phosphorylated moieties, which are often non-linearly related
to plasma pro-drug concentrations [15,17,46]. As a consequence,
plasma pro-drug concentrations may poorly predict pharmaco-
logical activity [47,48]. For NRTIs it is therefore necessary to
model the pharmacokinetics of the active intracellular form
explicitly. Here, we followed a step-wise model building process
to establish the link between plasma pro-drug and intracellular
TFV-DP pharmacokinetics, where we first independently estimat-
ed intracellular TFV-DP elimination. Statistic model evaluation
using typical- vs. individual estimates of the elimination rate
constant kout indicated that taking intracellular pharmacokinetic
variations into account does not only improve the prediction of
intracellular TFV-DP concentrations (see Fig. 2D), but also
improves the prediction of viral decay following TDF mono-
therapy with different doses (see Text S1). Notably, we predicted a
large variation for the kout parameter (range: 0.002–0.026 h
{1),
which is, however, within the confidence interval of previous
estimates (confidence interval: 0.0007–0.0372 h{1) [14]. The
typical half life of TFV-DP was very large
(gt1=2~ ln (2)=gkout&125h; range: 26–386h), which is in good
agreement with other studies [14,49,50]. Due to the lack of
intracellular TFV-DP pharmacokinetic data illuminating the
Figure 4. Viral load log10 kinetics during- and after 28 days of TDF mono-therapy. Black dashed vertical lines indicate the withdrawal of
TDF dosing. Solid lines represent predicted median viral kinetics using the coupled PK-PD model, whereas dashed lines represent the observed viral
kinetics [12]. Once daily 75mg TDF dosing. B: Once daily 150 mg TDF dosing. C: Once daily 300 mg TDF dosing. D: Once daily 600 mg TDF dosing.
doi:10.1371/journal.pone.0040382.g004
PK-PD of TDF andProphylactic Efficacy against HIV
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e40382
uptake of this specimen, we estimated the kinetics of influx/
anablism of intracellular TFV-DP (and the IC50 value) by
comparing viral decay kinetics following 28 days of TDF mono-
therapy with different doses. Based on model comparison, we
found that a saturable influx with individual (maximally achiev-
able) influx rates would best describe the pharmacodynamic data.
Notably, others [13,14] also found a saturable uptake based on
pharmacokinetic data alone (without taking viral decay into
account) and found a large variation in the uptake rate [14],
consistent with our findings. The saturable uptake kinetics
translate into maximally achievable TFV-DP concentrations,
which results in maximally achievable viral decay upon increasing
doses of TDF. As can be seen in Fig. 4C & D (dashed lines)
clinically measured viral decay from [12] appears to be greater for
300- vs. 600 mg TDF, which was not reproduced by our model
predictions (solid lines in Fig. 4C & D). The authors of the clinical
report [12] however stated that the difference in viral decay
between the two doses was not significant and may be attributed to
noise and the small size of the population tested (8 individuals for
each dose respectively in [12]) rather than having a mechanistic
reason.
In previous studies, average plateau TFV-DP concentrations
from different studies were in the range 80 to 160 fmol/106cells
[3,14], whereas the individual TFV-DP concentrations varied
between 10.6 to 441 fmol/106cells [14] when 300 mg oral TDF
was administered once daily. Our model predicted average plateau
levels were 130 fmol/106cells (range: 52–327 fmol/106cells; see
Fig. 3B), which is consistent with previous findings. TFV-DP
accumulates very slowly, owing to its long half life. We estimated
that plateau concentrations will be achieved after 21 dosing events
(range: 10–36), which is in the range of previous pharmacologic
considerations [3] (23 once daily dosing events). The slow
Figure 5. Predicted % infections prevented by distinct TDF-based prophylactic strategies for various parameter sets. A: Predicted %
infections prevented by once daily 300 mg TDF taken at different levels of adherence and with distinct virus inoculum sizes. , prophylactic
efficacy depends on adherence at the pv 0.05 or pv 0.01 level respectively. B: Predicted % infections prevented by a one week 300 mg TDF (1w-
PrEP/PEP) when started at distinct times before/after exposure with distinct numbers of viruses. , prophylactic efficacy depends on the timing of
start of TDF administration at the pv 0.05 or pv 0.01 level respectively. C: Predicted % infections prevented by a single dose 300 mg TDF (sd-PrEP)
when taken at distinct times before exposure with distinct virus inoculum sizes. , prophylactic efficacy depends on the timing of TDF single dose
administration at the pv 0.05 or pv 0.01 level respectively. D: Predicted % infections prevented by a single dose 600 mg TDF (sd-PrEP) when taken
at distinct times before exposure with distinct virus inoculum sizes. Error bars represent confidence bounds calculated using Greenwood’s formula.
zzz prophylactic efficacy depends on the inoculum size. The predicted probability of infection in the absence of drugs P(inf :DVt0 ,w) was 10+1:3%,
40+2:1%, 87+1:5% and 100+0% when Vt0 =1, 5, 20 or 100, respectively, viruses were inoculated.
doi:10.1371/journal.pone.0040382.g005
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accumulation of TFV-DP limits its prophylactic use as a single
dose drug, although prophylactically effective concentrations may
already be achieved § 24h after a single dosing event in some
patients (see Fig. 3A). In the absence of data reporting TFV-DP
concentrations in PBMCs after a single 300 mg oral TDF dose we
are, however, not able to directly verify these predictions. Notably,
very similar TFV-DP concentrations in rectal tissue biopsies after a
single 300 mg oral TDF dosing event were observed by Patterson
et al. in a very recent study [51] (discussed later on).
As suggested by Piliero et al. [47], the intracellular half life of
phosphorylated NRTIs is a key determinant of their clinical
efficacy. Often, however, the typical half life from different
individuals is taken as a reference and inter-individual differences
in the pharmacokinetics of activated NRTI anabolites are
neglected. In the case of TDF, large variations in the intracellular
pharmacokinetics may exist, which warrant further investigation
in order to optimize its efficacy both for prophylaxis and
treatment.
We predicted that the long half life of intracellular TFV-DP
translates into desirable properties in the case of continuous PrEP,
which is pharmacologically ‘forgiving’ in the case of poor
adherence, if at least 40% of the pills are ingested (see Fig. 5A).
While these pharmacologic considerations have been previously
discussed [3], we are presenting a quantification of these effects by
combining pharmacokinetics, viral dynamics and stochastic
simulation in a single integrated in silico model.
It was recently suggested that the willingness to take pills may be
a major obstacle for the implementation of PrEP strategies in
practice [24]. In line with this statement, Donnel et al. [52] found
a significant difference in HIV infection between individuals with
detectable vs. undetectable TFV in blood. Of note, for the levels to
drop from 70 ng/mL (median concentrations in [52]) tov0:1 ng/
mL (limit of detection in [52]), patients require to take less than
14% of their drugs (one out of seven doses), as TFV exhibits a long
terminal half life in plasma (&19 h). This indicates that the
willingness to take daily medication for HIV prevention may be
extremely low in some individuals with undetectable drug
(adherence v14%). It also raises concern that willingness to take
PrEP may in fact be a major obstacle for the implementation of
PrEP in practice as considered by Van Damme et al. [24]. The
results by Donnel et al. [52] and Van Damme et al. [24] also
indicate and that the estimates of PrEP efficacy may have been
contaminated by extremely poor adherence of some individuals in
the trials. In agreement with this assumption, clinical outcomes
with TDF-based continuous PrEP indicate highly variable
outcomes: from either being inefficient (FEM-PrEP) [19] to 44–
73% reduced HIV acquisition [20–22]. A sub-study of Partners
PrEP assessed the efficacy of continuous 300 mg daily TDF
administered to the healthy partner in sero-discordant couples in
Kenya and Uganda. The overall efficacy was 62% (confidence
interval: 34%;78%) and may be higher in adherent patients [24].
We predicted a prophylactic efficacy of 65%–80% for inoculum
size 1–5 in patients that take at least 40% of their drugs, see
Fig. 5A. In view of the possible contamination of Partner PrEP
trials results by extremely poor adherence in some individuals, our
slight overprediction of TDF efficacy may be anticipated. Further
analysis is required in order to assess the proportion of individuals
with sufficient adherence.
In the case of short-course pre-exposure TDF, or post-exposure
TDF, prophylactic success is limited by a slow accumulation of the
intracellular active component TFV-DP (only &20% infections
are prevented if TDF is taken 1h before exposure, see Fig. 5B, C,
D and Table S4, S5, S6. Note also that intracellular TFV-DP may
require 21 dosing events on average to reach plateau levels, see
Fig. 0B. In view of the recent approval of Truvada (300 mg TDF
+200 mg emtricitabine) for pre-exposure prophylaxis by the FDA,
prescribers should inform their patients about these potential
shortcomings, in order to avoid HIV-1 infection by inadequate use
of prophylaxis in combination with risk compensation [53]. HIV-
infection in combination with the inadequate use of PrEP may also
select drug resistance, which could limit treatment perspectives for
infected individuals. In terms of short-course pre-exposure
prophylaxis other drugs may be more suitable that accumulate
rapidly, such as nevirapine [37], which is successfully used for
prevention of mother-to-child infection.
Based on the model parameters, the duration of action required
to ensure that virus particles are eliminated with e.g. 99%






clv =CL+bT(t)?TU+bM(t)?MU. For the parameters used
Telim(99%)v3 days would suffice for inoculum sizes
Vt0[f1,5,20,100g. Taken together, this may indicate that,
pharmacologically, single dose PrEP drugs taken shortly before
potential viral exposure are required to accumulate rapidly in
target cells, but may not have to persist for more than 3 days, in
line with the pharmacological attributes of most NNRTIs.
In contrast to our predictions (Fig. 5B), some non-human studies
found that TDF-based post-exposure prophylaxis may be highly
efficient: Tsai et al. [42] treated macaques for variable durations
after exposure with SIVmne and tested viral markers. In their non-
human model of TDF-based PEP, viral titers remained undetect-
able in some monkeys until week 48 post-exposure, indicating that
some protection was achieved, in particular for longer durations of
PEP (28 days) and timely start of prophylaxis (within 24 hours
post-exposure) [42]. It was however argued [54] that TDF-PEP
Figure 6. Predicted % infections prevented vs. intracellular
TFV-DP concentrations for distinct virus inoculum sizes. The
solid blue-, dash-dotted green, dashed red and dotted black lines show
the concentration-response profile for virus inoculum size 1, 5, 20 and
100 respectively. The thick dashed horizontal black line indicates the
TFV-DP concentration, which prevents 50% of infections (EC50). The
dark grey area indicates the TFV-DP concentration range achieved
during once daily 300 mg oral TDF dosing with 100% adherence,
whereas the light grey extension to the left indicates the range of
concentrations resulting from imperfect adherence. Predictions are
based on the approximate analytic solution derived in Text S2.
doi:10.1371/journal.pone.0040382.g006
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may enhance immune controlled viral replication down to
undetectable levels, rather than actually preventing infection.
Furthermore, the efficacy in the primate model were depending on
the type of virus used [43] (which are SIV strains, not HIV-1) and
may also depend on the particular pharmacokinetics in the
primate model, which may be different to the human. Altogether,
the non-human studies with TDF-based PrEP may not translate
into human.
It is not precisely known how much virus is being transmitted
from an infected to an uninfected individual during e.g. sexual
contact. Moreover, it is not known how many transmitted viruses
actually reach a target cellular environment that allows their
reproduction, and what types of cells are relevant for the initial
infection. Also, the number of transmitted viruses, the availability
of target cells and the subset of viruses that reach a cellular
environment that facilitates their reproduction may be altered by
the circumstances of HIV-1 transmission and several unknown co-
factors. While the earliest stages of mucosal transmission of HIV-1
have not been directly observed in human and are not fully
understood, animal experiments suggest that CD4z T-cells are
probably the principal cell type infected at the portal of entry and
throughout the earliest stages of infection [55]. These cells are
mainly located in the sub-mucosa [56]. Although exposure at the
mucosal surface may be substantial, only a fraction of HIV-
particles may penetrate the intact epithelial layer and reach target
cells [57–59] (denoted as inoculum size throughout the manu-
script). Low per-contact infection probabilities further indicate that
infectious virus may not reach a cellular environment that
facilitates their reproduction during most sexual contacts [33,34]
(per-contact infection probabilities %5%), in contrast to other
routes of transmission such as blood transfusion [34] (per-contact
infection probabilities w95%). Recent studies further showed,
based on genotyping, that most infections (§75%) resulting from
sexual HIV-1 transmission can be traced back to a single founder
virus, or small populations of founder viruses [35,36]. Since the
majority of new infections result from sexual HIV-1 transmission,
PrEP intervention strategies may already effectively curb sexual
HIV-1 transmission by preventing infection with small virus
inoculum sizes. However, in the presence of co-existing infections,
the integrity of the mucosal barrier may be compromised, which
increases inoculum size [60]. Furthermore, co-existing infections
may increase HIV-1 acquisition by increasing the availability of
target cells in the sub-mucosa [60]. While we did not take co-
infections into account, future research is warranted to elucidate
the role of co-infections in the context of PrEP-strategies.
Our predictions revealed that the prophylactic efficacy of TDF
decreases with an increasing number of inoculated viruses (see
Fig. 5A, B, C, D), making TDF more efficient when only a few
viruses reach a target cell environment and less efficient for large
numbers of viruses. This observation can be explained as follows:
a) At clinically relevant concentrations, TDF may only inhibit a
certain proportion of potential target cell infections P. b) Some
minimum number of infectious viruses Vmin may already result in
infection with almost 100% probability. When only a proportion
of potential target cell infections are prevented, some inoculum
size Vt0 exists where P
:Vt0wVmin. Therefore, TDF becomes
inefficient above a certain inoculum size. The effect of TDF is
particularly limiting, if P cannot be decreased by increasing TDF
dosage (TFV uptake & anabolism become saturated, see eq. (5)
and grey range in Fig. 6).
While it has recently been suggested to combine antiviral
strategies for HIV-1 prevention [61], in this work, we predict a
dependency of PrEP efficacy on inoculum size, which could make
combined HIV prevention efforts synergistic: ‘test and treat’/
’treatment as prevention’ strategies [62] aim to reduce the
infectiousness of seropositive individuals by initiating HAART
immediately after diagnosis, which effectively down-sizes their
viral load and therefore the number of viruses transmitted to an
uninfected individual. We predict that PrEP is highly efficient in
the scenario where only few viral particles become transmitted,
which possibly makes the two HIV-prevention efforts synergistic.
This assumption, however, warrants further experimental confir-
mation.
The developed model is based on several assumptions, which we
outline in the following:
a) We used intracellular TFV-DP concentrations in PBMCs as a
marker of efficacy. PBMCs are surrogate markers, which
consist of different cell types of which the majority, however,
is susceptible to HIV-1 infection [26]. Different cell types may
differentially phosphorylate TFV, depending on the expres-
sion of transporters and enzymes relevant to the intracellular
phosphorylation of this drug. In line with this argument,
Patterson et al. [51] recently found higher levels of TFV-DP
in tissue biopsies from the rectum as compared to cervix and
vagina after a single dose of Truvada (300 mg TDF and
200 mg emtricitabine). Remarkably, the median concentra-
tions of TFV-DP in the rectal biopsies (displayed in units
fmol/g tissue in [51]) are within the same range as those
concentrations predicted in Figure 3A after unit conversion
(1 fmol/106 cells &106=180 fmol/mL tissue; 1 mg tissue
&1 mL tissue). However, it is not entirely clear, what
implications the distinct TFV-DP levels detected by Patterson
et al. [51] may have in terms of HIV-1 prophylaxis: Only a
subset of cells in the genital/rectal biopsies may be relevant
for HIV-1 infection (e.g. CD4z lymphocytes [55]). Thus, it is
not entirely clear if e.g. lower TFV-DP concentrations in
these biopsies imply lower concentrations in cells relevant to
HIV-1 infection or only in those not relevant to infection.
Human studies, which analyze TFV-DP levels in purified
CD4z cells, are missing. Purified CD4z cells derived from
rectal biopsies in macaques indicate identical TFV-DP levels
when compared to PBMC levels, which suggests that the
PBMC surrogate marker is a good indicator for TFV-DP
levels in cells relevant to HIV-1 infection.
b) Recent work suggests that the efficacy of NRTIs like TDF is
affected by the levels of endogenous competing nucleotides
dNTP (specifically: dATP for TFV-DP) [6,63]. Although this
is likely to contribute to the efficacy of TFV-DP to prevent
particular routes of infection, we could not take this
information into account, because information concerning
dNTP levels in target cells in different physiologic locations is
lacking for humans. However, once these levels become
available, their impact on the (cell-specific) susceptibility may
be probed by sophisticated models, such as [6].
c) Vaginal TFV gel has been used successfully to prevent
heterosexual HIV-1 infection [64]. Vaginal TFV gel exhibits
entirely different pharmacokinetics compared to oral TDF
dosing. TFV-DP levels in vaginal lymphocytes may be
significantly higher in relation to the systemic levels (TFV-
DP in PBMCs) after local exposure [65,66]. Most impor-
tantly, local exposure may mitigate the need for dosing long
before exposure, which may be the greatest obstacle for the
sucess of oral PrEP in practice. While the current model is
useful in predicting the effects of oral TDF administration on
HIV-1 infection, sophisticated pharmacokinetic modelling of
vaginal TFV gel [67] in combination with stochastic
PK-PD of TDF andProphylactic Efficacy against HIV
PLoS ONE | www.plosone.org 11 July 2012 | Volume 7 | Issue 7 | e40382
modelling may enable to assess its prophylactic efficacy in
silico in the future.
d) In the absence of data elucidating the levels of TFV-DP in
uninfected individuals, we assumed that TFV-DP levels in
PBMCs from infected individuals vs. uninfected individuals
are similar. Since TFV pharmacokinetics (parent compound)
have been reported to be similar in healthy- and HIV-
infected individuals [5], we found it reasonable to assume that
TFV-DP levels are also similar.
e) It has recently been reported that TFV may become
phosphorylated within red blood cells (RBCs) [68]. While
standard procedures for the preparation of PBMC samples
may not prevent their contamination with RBCs, this may
hamper the accuracy of determination of TFV-DP in PBMC
samples. Therefore, differences in RBC contamination may
in part contribute to the variability of TFV-DP levels in
PBMC measurements. The relevance and impact of RBC
contamination on TFV-DP levels is not yet fully understood
and further research is warranted to assess its role.
f) In individuals with established infection, the rates of viral
elimination CL(infected) have been determined in a number
of clinical studies, see e.g. [69,70]. Because of ethical reasons,
the elimination of HIV in uninfected/newly infected
individuals CL(naive) has never been directly observed.
We assumed that viral elimination CL(naive) is lower in
uninfected than in infected individuals, because the immune
system may not recognize HIV readily in the naive patient. In
line with other studies [71,72], we therefore set the parameter
CL(naive)=2.3 [1/day] (see Table 2), which reproduced
clinical infection probabilities in previous work [37].
The presented modeling approach may be extended to e.g.
assess the consequences of TDF-based PrEP intervention on drug
resistance emergence, or TDF-based PrEP efficacy in the case
when resistant virus becomes transmitted. Also, the combined
effects of emtricitabine (FTC) and TDF remain to be elucidated,
but can be studied by extending the presented model with the
pharmacokinetics of FTC, once data on intracellular FTC-
triphosphate becomes available.
Supporting Information
Table S1 Assessment of alternative models for plasma
TFV pharmacokinetics. Goodness-of-fit in terms of the
weighted residual sum of squared errors (WRSE) of model
predicted vs. experimental data following either doses of 75,
150, 300 or 600 mg oral TDF from three independent clinical
trials [7,9,12] for a one compartment- vs. a two compartment
model. The models were compared by computing the Akaike
information (AIC) and the model with the lowest AIC value was
used subsequently (the two compartment model). Goodness-of-fit
plots are shown in Fig. 2A-B (main article).
(PDF)
Table S2 Predicted individual TFV-DP elimination
kinetics. Estimated individual plateau concentrations C0(i) and
elimination rates kout(i) of TFV-DP from PBMCs (after treatment
cessation). Parameters were estimated assuming first-order decay
kinetics according to: Ccell(i,t)~C0(i):e
{t:kout(i) using the data
from [11].
(PDF)
Table S3 Contingency table for infection events during
once daily PrEP with 300 mg TDF. Predictions are based on
2000 ‘virtual patients’ simulations respectively. The first number in
the brackets in columns 2–6 indicates the number of ‘virtual
patients’ that remained uninfected after viral challenge, whereas
the second number indicates the number of patients that became
infected. For example, when 20% of once daily 300 mg TDF pills
are ingested and patients are challenged with inoculum size one
(one virus reaches a target cell environment), 1927 ‘virtual
patients’ remain uninfected, whereas 73 became infected.
(PDF)
Table S4 Contingency table of infection events for one
week of TDF-based PrEP with 300 mg started around
the time of exposure (1w-PrEP/PEP). Predictions are based
on 2000 ‘virtual patients’ simulations respectively. The first
number in the brackets in columns 2–6 indicates the number of
‘virtual patients’ that remained uninfected after viral challenge,
whereas the second number indicates the number of patients that
became infected. For example, when 300 mg TDF is taken 6
hours before viral challenge, continued for one week and patients
are challenged with inoculum size one (one virus reaches a target
cell environment), 1866 ‘virtual patients’ remain uninfected,
whereas 134 became infected.
(PDF)
Table S5 Contingency table of infection events for a
single oral TDF dose 300 mg (sd-PrEP). Predictions are
based on 2000 ‘virtual patients’ simulations respectively. The first
number in the brackets in columns 2–6 indicates the number of
‘virtual patients’ that remained uninfected after viral challenge,
whereas the second number indicates the number of patients that
became infected. For example, when 300 mg TDF are taken
1 hour before viral challenge and patients are challenged with
inoculum size one (one virus reaches a target cell environment),
1818 virtual patients remain uninfected, whereas 182 became
infected.
(PDF)
Table S6 Contingency table of infection events for a
single oral TDF dose 600mg (sd-PrEP). Predictions are
based on 2000 ‘virtual patients’ simulations respectively. The first
number in the brackets in columns 2–6 indicates the number of
‘virtual patients’ that remained uninfected after viral challenge,
whereas the second number indicates the number of patients that
became infected. For example, when 600mg TDF are taken 1hour
before viral challenge and patients are challenged with inoculum
size one (one virus reaches a target cell environment), 1839 virtual
patients remain uninfected, whereas 161 became infected. zzz
Table 2. Parameters used for the viral model.
Param. Value Ref. Param. Value Ref.
lT 2:109 [73] lM 6:9:107 [74]
dT,dT1 0.02 [74] dM,dM1 0.0069 [74]
dT2 1 [69] dM2 0.09 [29]
b:q:rPR 0.67 [29] rrev 0.5 [31]
dPIC,T 0.35 [21,75] dPIC,M 0.0035 [29]
kT 0.35 [31] kM 0.07 [29]
bT(w) 8:10
{12 [76] bM(w) 10
{14 [29]
bNT 1000 [74] bNM 100 [74]
CL(infected) 23 [70] CL(naive) 2.3 [71,72]
All parameters refer to the absence of drug treatment w. All parameters in units
[1/day], except rrev and b
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Inoculum size has a significant impact on the number of infections
at the pv0.01 level (x2-test).
(PDF)
Table S7 Statistical test of difference of prophylactic
efficacy between 300 mg sd-PrEP and 600 mg sd-PrEP
with TDF. The distinct fields show the p-value for a x2-test
between the prophylactic efficacy between 300 mg and 600 mg
sd-PrEP with TDF. The predicted outcome was significantly
different between the two distinct dosing regimens, if the p-value is
pv0.05, or pv0.01 respectively (yellow- and red-shaded fields).
(PDF)
Text S1 The supplementary text contains the derivation
of the model for intracellular TFV-DP uptake and
anabolism as well as a model evaluation.
(PDF)
Text S2 The supplementary text contains the derivation
of an approximate analytical formula for the computa-
tion of the probability of infection with distinct virus
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